At a glance
ClinicalIndex Comparison RecordN/ACompleted· 466 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Defining Cut-off Values for Widely-used Composite Scores and Patient-reported Outcome Measures in Psoriatic Arthritis Corresponding to Remission and Flare Assessed by the Physician and the Patient
In Brief
An observational study for Psoriatic Arthritis. Completed, enrolled 466 participants across 22 sites in 14 countries.
Detailed Summary
The purpose of this study is to define cut-off values of the most widely used composite scores and patient-reported outcomes, for levels corresponding to remission/low disease activity and for changes in levels corresponding to flares, in PsA, when remission/low disease activity and flare are defined from the patient and physician perspective. The ReFlaP (Remission/Flare in PsA) study is a prospective, multicentric international, longitudinal, observational study.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriatic Arthritis
CountriesAustria, Brazil, Canada, Estonia, France, Germany, Italy, Romania, Russia, Singapore, Spain, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
First PostedApr 2017
Enrollment StartMay 2017
Primary CompletionJan 2018
Study CompletionJul 2018
TodayJul 2026
First PostedApr 19, 2017
Enrollment StartMay 18, 2017
Primary CompletionJan 30, 2018
Study CompletionJul 30, 2018
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 9.2 years ago